Anixa Biosciences shares surge 10.12% after hours as company assumes full control of breast cancer vaccine IND application, advancing to Phase 2 trials.

Anixa Biosciences surged 10.12% in after-hours trading following the announcement that it has assumed full sponsorship of the IND application for its breast cancer vaccine from the Cleveland Clinic, enabling the imminent start of a Phase 2 clinical trial. The move, a strategic advancement after positive Phase 1 results showing a 74% immune response in participants, grants the company operational independence to lead the multi-site Phase 2 study. This transition underscores the vaccine’s prioritization within Anixa’s pipeline and could stabilize investor sentiment amid recent volatility. The stock’s after-hours rebound aligns with the clinical milestone, reflecting optimism over the trial’s design and potential combination with Keytruda.